Immunohistochemical investigation of transitional cell carcinoma of the upper urinary tract



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper reviews the data available in the literature in immunohistochemical investigation of transitional cell carcinomas of renal pelvis and ureter. The classical tumour characteristics of transitional cell carcinoma of the upper urinary tract - pathological stage and grade.Traditional morphological criteria are not sufficient to precisely predict the biological behavior of transitional cell carcinomas of renal pelvis and ureter. Immunohistochemical investigation gives additional prognostic information in patients with transitional cell carcinoma of the upper urinary tract.

Full Text

Restricted Access

References

  1. Матвеев Б.П., Фигурин К.М. Диагностика опухолей верхних мочевых путей // Урол. и нефрол. 1998. № 5. С. 29-34.
  2. Djoldc М., Hadzi-Djokic J., Nikolic J. et al. Tumors of the upper urinary tract: results of conservative surgery //Prog. Urol. 2001. Vol. 11 (6). P. 1231-1238.
  3. Palou J., Salvador J., Millan F. et al. Management of superficial transitional cell carcinoma in the intramural ureter: what to do? // J. Urol. 2000. Vol. 163 (3). P. 744-747.
  4. Комяков Б.К. Диагностика и оперативное лечение опухолей верхних мочевых путей // Урол. и нефрол. 1998. №3. С. 18-21.
  5. Комяков Б.К., Идрисов Ш.Н., Новиков А.И., Гулиев Б.Г, Эль-Аттар Т.Х. Оперативное лечение эпителиальных опухолей верхних мочевыводящих путей // Урология. 2004. № 4. С. 12-16.
  6. Комяков Б.К., Гулиев Б.Г, Карлов П.А., Эль-Аттар Т.Х. Органосохраняющие операции при опухолях верхних мочевыводящих путей // Онкоурология. № 2. 2007. С. 26-29.
  7. Herr Н., Cookson М., Soloway S. Upper tract tumors in patients with primary bladder cancer followed for 15 years // J. Urol. 1996. Vol. 156 (4). P. 1286-1287.
  8. Jabour M., Desgrandchamps F., Cazin S. et al. Percutaneous management of grade II upper urinary tract transitional cell carcinoma: the long-term outcome // J. Urol. 2000. Vol. 163 (4). P. 1105-1107.
  9. Keeley F., Bibbo M., Bagley D. Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma // J. Urol. 1997. Vol. 157 (5). P. 1560- 1565.
  10. El Fettouh FI., Rassweiler J., Schulze M. et al. Laparoscopic radical nephroureterectomy: results of an international multicenter study // Eur. Urol. 2002. Vol. 42 (5). p. 447^152.
  11. Rural A., Demirkesen O., Arar O. et al. Modified «pluck» nephroureterectomy for upper urinary tract disorders: combined endourologic and open approach // J. Endourol. 1997. Vol. 11 (2). P. 131-134.
  12. Shalhav A., Dunn М., Portis A. et al. Laparoscopic nephroureterectomy for upper tract transitional cell cancer: the Washington University experience // J. Urol. 2000. Vol. 163 (4). P. 1100-1104.
  13. Alcao J., Matsuyama H., Yamamoto Y. et al. Clinical significance of lymphovascular invasion in upper urinary tract urothelial cancer // BJU Int. 2008. Vol. 102 (5). P. 572-575.
  14. Gupta R., Paner G., Amin M. Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting //Adv. Anat. Pathol. 2008. Vol. 15 (3). P. 127-139.
  15. Kumano M., Furukawa J., Yamanaka K. et al. Pathological prognostic factors of renal pelvic and ureteral cancer // Nippon Hinyokika Gakkai Zasshi. 2006. Vol. 97 (6). P. 786-790.
  16. Guan Y., Li N., Zhou L., He Z., Li M., Na Y. Study of prognostic factors of ureter cancer // Zhonghua Wai Ke ZaZhi. 2007. Vol. 45 (18). P. 1260-1263.
  17. Brown G., Matin S., Busby J. et al. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy // Urology. 2007. Vol. 70 (2). P. 252-256.
  18. Ко R., Chew B., Hickling D. et al. Transitional-cell carcinoma recurrence rate after nephroureterectomy in patients who undergo open excision of bladder cuff v transurethral incision of the ureteral orifice // J. Endourol. 2007. Vol. 21 (7). P. 730-734.
  19. Kondo T., Nakazawa H., Ito F. et al. Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract//J. Urol. 2007. Vol. 178 (4). P. 1212-1217.
  20. Wu C., Pang S., Chen C. et al. The impact factors on prognosis of patients with pT3 upper urinary tract transitional cell carcinoma // J. Urol. 2007. Vol. 178 (2). P. 446-450.
  21. Fujii Y., Okuno T. et al. Adjuvant chemotherapy with MVP-CAB (methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin and bleomycin) for epithelial tumors of the upper urinary tract // Hinyokika ICiyo. 1992. Vol. 38(1). P.55-59.
  22. Terrell R., Cheville J. et al. Histopathological features and p53 nuclear protein staining as predictors of survival and tumor recurrence in patients with transitional cell carcinoma of the renal pelvis // J. Urol. 1995. Vol. 154(4). P. 1342-1347.
  23. Rey A., Lara P., Redondo E. et al. KI67 proliferation index in tumors of the upper urinary tract as related to established prognostic factors and long-term survival //Arch. Esp. Urol. 1998. Vol. 51 (2). P. 204-210.
  24. Kuroda N., Shimasaki N., Miyazaki E. et al. The distribution of myofibroblasts and CD34-positive stromal cells in normal renal pelvis and ureter and their cancers//Histol. Histopathol. 2006. Vol. 21 (12). P. 1303- 1307.
  25. Kamijima S., Tobe T., Suyama T. et al. The prognostic value ofp53, Ki-67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter// Int. J. Urol. 2005. Vol. 12 (11). P.941-947.
  26. Moreno Sierra J., Fernandez C., Mazuecos Lypez M. et al. Systematic review about the usefulness and prognostic value of the p53oncoprotein and proliferation marker Ki-67 for upper urinary tract transitionalcell carcinoma // Arch. Esp. Urol. 2004. Vol. 57 (3). P. 327- 335.
  27. Watanabe J., Nishiyama H., Okubo K. et al. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY // Urology. 2004. Vol. 63 (5). P. 989-993.
  28. Watanabe J., Nishiyama H., Kawanishi FI. et al. Clinical evaluation of serum p53 antibodies in patients with upper urinary tract tumors // J. Urol. 2005. Vol. 174 (1). P. 73-75.
  29. Dalbagni G., Ren Z., Hen- H., Cordon-Cardo C., Reuter V. Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study // Clin. Cancer Res. 2001. Vol. 7(9). P.2797-2801.
  30. Hashimoto LI., Sue Y., Saga Y., Tokumitsu M., Yachiku S. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter // Int. J. Urol. 2000. Vol. 7(12). P. 457-463.
  31. Bjerkehagen B., Fosse S., Raabe N., Holm R., Nesland J. Transitional cell carcinoma of the renal pelvis and its expression of p53 protein, c-erbB-2 protein, neuron-specific enolase, Phe 5, chromogranin, laminin and collagen type IV // Eur. Urol. 1994. Vol. 26 (4). P. 334-339.
  32. Petersen I., Ohgalci H., Ludeke B.I. et al. p53 mutations in phenacetin-associated human urothelial carcinomas //Carcinogenesis. 1993. Vol. 14(10). P. 2119-2122.
  33. Lin H., Huang C, Wu W. et al. Mutation of the p53 tumor suppressor gene in transitional cell carcinoma of the urinary tract in Taiwan. Kaohsiung // J. Med. Sci. 2005. Vol. 21 (2). P.57-64.
  34. Zigeuner R., Tsybrovslcyy O., Ratschek M. et al. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma // Urology. 2004. Vol. 63 (6). P. 1079-1083.
  35. Fontana L., Gai-сна G., Areas M. et al. The expression ofp53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival //Arch. Esp. Urol. 2002. Vol. 55 (7). P. 792-726.
  36. Joung J., Yang S., Jeong I. et al. Identification of immunohistochemical factors that predict the synchronous or metachron ous development of bladder tumors in patients with upper urinary tract tumors // Urol. Int. 2008. Vol. 81 (3). P. 306-311.
  37. Fromont G., Roupnct M., Amira N. et al. Tissue microarray analysis of the prognostic value of E-cadherin, КІ67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma // Eur. Urol. 2005. Vol. 48 (5). P. 764-770.
  38. Lindemann-Docter K., Knechel-Clarke R. Histopathology of urothelial carcinomas: crucial for patient management//Urologe A. 2008. Vol. 47 (5). P. 627-636.
  39. Furihata M., Sonobe H., Ohtsuki Y. et al. Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia // J. Pathol. 1996. Vol. 178 (2). P. 133-139.
  40. Ordonez N. Significance thrombomodulin immunostaining in diagnostic carcinoma of the renal pelvis // Hystopathology. 1997. Vol. 31 (6). P. 517-524.
  41. Dexeus F., Logothetis C., Sella A. et al. Serum biomarkers in metastatic renal cell carcinoma // Urology. 1991. Vol. 38(1). P.6-10.
  42. Ikemoto S., Iimori H. Two cases urothelial cancer with high serum levels of carcinoembryonic antigen and TA- 4 // Int. Urol. 1993. Vol. 51 (2). P. 105-107.
  43. Fujii Y., Okuno T., Masuda M., Hirokawa M., Iwabuchi K. A case of transitional cell carcinoma of renal pelvis with extremely high serum levels of carcinoembryonic antigen (CEA) // Hinyokika Kiyo. 1992. Vol. 38 (1). P. 55-59.
  44. Kato S., Yasuda M., Nakano M. et al. Superficial urothelial carcinoma of ureter with elevated serum CA19- 9 and CEA// Hinyokika Kiyo. 2004. Vol. 50 (2). P. 99- 102.
  45. de Pinieux G., Colin D., Vincent-Salomon A. et al. Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER- 2/ neu (c-erbb-2) status in urothelial carcinoma // Virchows Arch. 2004. Vol. 444 (5). P. 415-419.
  46. Nakanishi K., Tominaga S., Hiroi S. et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract // Virchows Arch. 2002. Vol. 441 (6). P. 559-563.
  47. Sejima T., Miyagawa I. Expression bcl-2, p53 oncoprotein, proliferating cell nuclear antigen (PCNA) in transitional cell carcinoma of the renal pelvis // Eur. Urol. 1999. Vol. 35 (3). P. 242-248.
  48. Nakanishi K., Tominaga S., Kawai T. et al. Expression bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract, the renal // Virchows Arch. 1998. Vol. 432 (5). P. 445-450.
  49. Noto K., Fujime M., Isobe H. et al. Determination of urinary CA19-9 levels in urothelial cancer-assessment of its role in diagnosis // Nippon Hinyokika Gaklcai Zasshi. 1997. Vol. 88 (3). P. 406-413.
  50. Болдарян H.A., Пожарисский K.M., Винокуров В.Л., Тен В.П., Самсонова Е.А. Прогностическое значение уровня экспрессии циклооксигеназ (СОХ-1, СОХ-2) при раке эндометрия (клиникоиммуногистохимическое исследование) // Вопр. онкол. 2008. Т. 54 (1). С. 40
  51. Kang С., Chiang Р., Huang S. Correlation of СОХ- 2 expression in stromal cells with high stage, high grade, and poor prognosis in urothelial carcinoma of upper urinary tracts tracts // Urology. 2008. Vol. 72 (1). P. 153-157.
  52. Miyata Y., Kanda S., Nomata K., Eguchi J., Kanetake H. Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract //J. Urol. 2005. Vol. 173 (1). P. 56-60.
  53. Bershadsky A.D., Vasiliev J.M. Cytoskeleton. New York: Plenum Press, 1988. 285 p.
  54. Петров C.B., Райхлин H.T. Руководство по иммунохимической диагностике опухолей человека. Казань, 2000.
  55. Moll R., Franke F.W., Schiller D.L. et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells // Cell. 1982. Vol. 31. P. 11-24.
  56. Moll R., Lowe A., Laufer J., Franke W.W. Cytokeratin 20 in human carcinomas: a new histodiagnostic marker detected by monoclonal antibodies // Am. J. Pathol. 1992. Vol. 140. P. 427-447.
  57. Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors // Intermediate filaments. 1998. Vol. 31. P. 205-262.
  58. Fuchs E. Intermediate filaments and disease: mutations that cripple cell strength // J. Cell Biol. 1994. Vol. 125 (3). P. 511-516.
  59. Miyata Y., Ohba K., Kanda S. et al. Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract // Virchows Arch. 2006. Vol. 448 (6). P. 822-829.
  60. Tsujimoto Y., Komori K., Tsujimoto M. et al. Immunohistochemical studies of p53, Ki-67, E-cadherin and beta-catenin on renal pelvic and ureteral cancers // Nippon Hinyokika Galdcai Zasshi. 2008. Vol. 99 (1). P. 1-6.
  61. Masuda M., Talcano Y., Iki M. et al. Expression and prognostic value of CD44 isoforms in transitional cell carcinoma of renal pelvis and ureter // J. Urol. 1999. Vol. 161 (3). P. 805-808.
  62. Ке H., Wei Y., Yang S. et al. Overexpression of hypoxia-inducible factor-1 alpha predicts an unfavorable outcome in urothelial carcinoma of the upper urinary tract // Int. J. Urol. 2008. Vol. 15 (3). P. 200-205.
  63. Gohji K., Fujimoto N., Komiyama T. et al. Expression of metalloproteinase-2, metalloproteinase-3 in transitional cell carcinoma of upper urinary tract // Cancer. 1996. Vol. 78 (11). P. 2379-2387.
  64. Miyata Y., Kanda S., Nomata K., Flayashida Y., Kanetake H. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival // Urology. 2004. Vol. 63 (3). P. 602-608.
  65. Kamai T., Talcagi K., Asami H. et al. Prognostic significance of p27Kipl and Ki-67 expression in carcinoma of the renal pelvis and ureter // Urology. 2000. Vol. 56 (2). P. 331.
  66. Eltz S., Comperat E., Cussenot O., Rouprict M. Molecular and histological markers in urothelial carcinomas of the upper urinary tract // В JU Int. 2008. Vol. 102 (5). P. 532-535.
  67. Cheville J., Terrell R., Cohen M.B. Use of proliferative markers Ki-67 (MIB-1) and proliferating cell nuclear antigen (PC 10) in transitional cell carcinoma of the renal pelvis // Mod. Pathol. 1994. Vol. 7 (7). P. 794- 800.
  68. Zhang X., Kong С, Takenaka I. Evaluation of cell proliferation, apoptosis, and angiogenesis in transitional cell carcinoma of the renal pelvis and ureter // Urology. 2001. Vol. 57 (5). P. 981-985.
  69. Kamijo T., Sato T., Yanagizawa R. et al. The expression of proliferating cell nuclear antigen (PCNA) immunostaining in renal pelvic and ureteral cancers and its prognostic value // Nippon Hinyokika Gakkai Zasshi. 1994. Vol. 85 (6). P. 938-944.
  70. Masuda M., Takano Y., Iki M. et al. Cyclin-dependent kinase inhibitor p27(Kipl) expression in transitional cell carcinoma of renal pelvis and ureter // J. Urol. 2000. Vol. 161 (3). P. 805-808.
  71. Kamai T, Takagi K., Asami H. et al. Prognostic significance of p27Kipl and Ki-67 expression in carcinoma of the renal pelvis and ureter // BJU Int. 2000. Vol. 86 (1). P. 14-19.
  72. Furihata M., Ohtsuki Y., Sonobe H. et al. Prognostic significance of cyclin E and p53 protein overexpression in carcinoma of the renal pelvis and ureter // Br. J. Cancer. 1998. Vol. 77 (5). P. 783-788.
  73. Shinohara M., Okazawa A., Suzuki M. et al. Clinical investigation of renal pelvic and ureteral cancer with special reference to adjuvant chemotherapy // Nippon Hinyokika Gakkai Zasshi. 1995. Vol. 86 (8). P. 1375-1382.
  74. Nakanishi K., Hiroi S., Tominaga S. et al. Expression of hypoxia-inducible factor-1 alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract // Clin. Cancer Res. 2005. Vol. 11 (7). P. 2583-2590.
  75. Lindemann-Docter K., Кпьсііеі-Clarke R. Histopathology of urothelial carcinomas: crucial for patient management // Urologe A. 2008. Vol. 47 (5). P. 627-636.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Komyakov B.K., Anichkov N.M., Makovskaya A.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies